| Market Cap | 1.44B 1.24B 1.17B 1.07B 2B 136B 2B 13.82B 5.36B 69.99B 5.43B 5.31B 225B | P/E 2026 * |
-360x | P/E 2027 * | 17.1x |
|---|---|---|---|---|---|
| Enterprise Value | 1.44B 1.24B 1.17B 1.07B 2B 136B 2B 13.82B 5.36B 69.99B 5.43B 5.31B 225B | EV / Sales 2026 * |
4.12x | EV / Sales 2027 * | 2.71x |
| Free-Float |
84.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Imprimis Pharmaceuticals Inc
| 1 day | +0.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 53 | 17/12/2011 |
Andrew Boll
PSD | President | 43 | 21/08/2025 |
Brett Burrell
CMP | Compliance Officer | - | 01/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Baum
CHM | Chairman | 53 | 19/08/2021 |
Perry Sternberg
BRD | Director/Board Member | 57 | 31/03/2022 |
Adrienne Graves
BRD | Director/Board Member | 71 | 26/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.83% | +11.11% | - | - | 1.44B | |
| -0.88% | -2.15% | +54.71% | +106.31% | 1,024B | |
| -1.15% | +2.68% | +53.97% | +71.50% | 663B | |
| -1.44% | +0.38% | +20.40% | +73.05% | 453B | |
| +0.14% | -0.47% | +29.49% | +38.56% | 352B | |
| -1.33% | +4.72% | +24.69% | +45.55% | 304B | |
| -1.15% | +0.30% | -1.49% | +12.31% | 252B | |
| -1.55% | +1.11% | +56.10% | +70.32% | 236B | |
| -0.88% | +1.15% | -17.09% | -54.39% | 206B | |
| -0.15% | +3.65% | +33.90% | +96.99% | 187B | |
| Average | -0.81% | +1.09% | +28.30% | +51.13% | 408.71B | |
| Weighted average by Cap. | -1.10% | +0.55% | +36.62% | +66.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 351M 302M 284M 259M 485M 33.11B 487M 3.36B 1.3B 16.99B 1.32B 1.29B 54.73B | 533M 458M 431M 394M 737M 50.28B 739M 5.09B 1.98B 25.8B 2B 1.96B 83.11B |
| Net income | -3.92M -3.37M -3.17M -2.9M -5.42M -370M -5.44M -37.51M -14.55M -190M -14.72M -14.4M -612M | 89.19M 76.75M 72.21M 65.96M 123M 8.42B 124M 853M 331M 4.32B 335M 328M 13.92B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
